Global HPAPIs and Cytotoxic Drugs Manufacturing Market 2016-2026 - U.S. Accounts for Around 23% of the Total HPAPI Production Facilities

Dublin, March 31, 2016 -- Research and Markets has announced the addition of the "HPAPIs and Cytotoxic Drugs Manufacturing Market (2nd Edition), 2016 - 2026" report to their offering.

The HPAPIs and Cytotoxic Drugs Manufacturing Market, 2016-2026 (2nd edition)' report provides an extensive study of the rapidly growing manufacturing market of HPAPIs and cytotoxic drugs. Due to their numerous advantages and widespread application in treatment of cancer and other disorders, HPAPIs and cytotoxics have emerged as one of the key focus areas of researchers across the globe.

When compared to conventional therapeutic products, these compounds offer multiple advantages including low dosage requirements, low cost and high target specificity. The focus of this report is primarily to understand the current competitive landscape and the likely future evolution of both the HPAPIs and cytotoxic drugs market over the next decade.

Though some pharmaceutical companies have in-house capabilities, the development of HPAPIs / cytotoxic drugs is primarily outsourced to contract manufacturers. The future growth of this market is likely to be driven by the increasing demand for oncology drugs, as majority of high potency and cytotoxic drugs are being developed for the treatment of cancer. As this segment continues to evolve, the use of HPAPIs and cytotoxic drugs in other therapeutic areas such as glaucoma, hormonal imbalances and respiratory disorders are also being investigated.

Despite their benefits and the scope of a promising future, the study also highlights that there are considerable challenges associated with the production of these compounds. Due to their highly toxic nature, they pose significant occupational hazards, if not handled carefully. In addition, cross-contamination with other products can be highly detrimental for the patients. Therefore, adequate containment strategies and a proper classification of hazards is essential for the uptake of this market.

The base year for this report is 2015; actual sales data of respective companies has been presented for up to last five years. The report provides market forecasts for the period 2016 - 2026. The research, analysis and insights presented in this report is backed by a deep understanding of key insights gathered both from secondary and primary research.

Amongst other elements, the report covers the following aspects:

- Review of the manufacturing sites of various CMOs involved in HPAPIs / cytotoxic drugs manufacturing.
- Overview of the pharmaceutical companies with in-house manufacturing capabilities.
- Investments in the expansion or for setting up of new facilities as well as collaborations that have taken place in the recent past.
- A detailed case study on the manufacturing of antibody drug conjugates (ADCs), one of the well-known emerging classes of cytotoxic drugs.

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. Market Overview

5. HPAPI Manufacturing Market

6. Cytotoxic Drugs Manufacturing Market

7. Case In Point: The One-Stop-Shops'

8. Market Size and Forecast

9. Leading CMOs in the US

10. Leading CMOs in the EU

11. Leading CMOs in Asia Pacific

12. Emerging CMOs

13. Recent Developments

14. SWOT Analysis

15. Case in Point: Contract Manufacturing in ADCs

16. Interview Transcripts

17. Conclusion

18 Appendix 1: Tabulated Data

19. Appendix 2: List of Companies and Organizations

Companies Mentioned - Partial List

- AAIPharma Services Corp.
- AB SCIEX
- AbbVie
- ACES Pharma
- ADC Biotechnology
- Aenova Group
- Aesica Pharmaceuticals
- Affinity Lifesciences
- Agno Pharma
- Ajinomoto Omnichem
- Alkermes Contract Pharma Services
- ALMAC Group
- Alphora Research
- Amatsigroup
- AMPAC Fine Chemicals
- AMRI
- Aptuit
- Arch Pharmalabs
- Ash Stevens
- Aspen Holdings
- Asymchem Laboratories
- AVANTHERA
- Avecia
- AzayaTherapeutics
- Bachem
- Banner Pharmacaps
- Baxter BioPharma Solutions
- Bayer
- Bend Research
- BioAgilytix Labs

For more information visit http://www.researchandmarkets.com/research/3lbfl6/hpapis_and

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]

         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900

         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716

         Sector: Oncology